Stock Events

Can-Fite Biopharma 

$3.01
15
-$0.2-6.23% Today

Statistics

Day High
3.36
Day Low
3.2
52W High
4.48
52W Low
1.81
Volume
134,477
Avg. Volume
107,727
Mkt Cap
4.95M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

1JunExpected
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
-3
-2
-1
0
Expected EPS
-0.19
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CANF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap81.06B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs in areas such as inflammation and oncology, similar to Can-Fite's focus areas.
Abbvie
ABBV
Mkt Cap297.71B
AbbVie operates in the same therapeutic areas as Can-Fite, including inflammation and cancer, making it a direct competitor in drug development.
AMGEN
AMGN
Mkt Cap160.19B
Amgen focuses on innovative therapeutics in areas like oncology and inflammation, directly competing with Can-Fite's product pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap83.52B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines in cancer and immune-inflammatory diseases, overlapping with Can-Fite's interests.
Pfizer
PFE
Mkt Cap156B
Pfizer engages in the discovery, development, and manufacture of healthcare products including medicines and vaccines for immunology and oncology, competing with Can-Fite.
Merck &
MRK
Mkt Cap327.95B
Merck operates in the pharmaceutical industry focusing on cancer and inflammatory diseases, making it a competitor to Can-Fite in these therapeutic areas.
Novartis
NVS
Mkt Cap231.52B
Novartis focuses on a broad range of healthcare areas including advanced therapy platforms in oncology and rheumatology, competing with Can-Fite's research and development.
Roche
RHHBY
Mkt Cap194.86B
Roche develops and markets medications and diagnostic instruments in oncology, immunology, and infectious diseases, areas that Can-Fite is also targeting.
Astrazeneca
AZN
Mkt Cap246.77B
AstraZeneca is a global, science-led biopharmaceutical business that operates in the main therapy areas of cancer and autoimmune diseases, directly competing with Can-Fite.
Johnson & Johnson
JNJ
Mkt Cap350.27B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a wide range of diseases, including those in Can-Fite's focus areas, making it a competitor.

Analyst Ratings

18$Average Price Target
The highest estimate is $18.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Show more...
CEO
Pnina Fishman
Employees
8
Country
US
ISIN
US13471N2018
WKN
000A2PJNP

Listings